Compare MAIN & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAIN | KRYS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.3B |
| IPO Year | 2007 | 2017 |
| Metric | MAIN | KRYS |
|---|---|---|
| Price | $62.28 | $245.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $61.57 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 450.6K | 272.8K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 6.84% | N/A |
| EPS Growth | 9.38 | ★ 275.72 |
| EPS | 6.03 | ★ 6.66 |
| Revenue | ★ $561,290,000.00 | $373,164,000.00 |
| Revenue This Year | $5.53 | $36.14 |
| Revenue Next Year | $2.24 | $41.80 |
| P/E Ratio | ★ $10.33 | $37.07 |
| Revenue Growth | 5.92 | ★ 54.51 |
| 52 Week Low | $47.00 | $122.80 |
| 52 Week High | $67.77 | $246.94 |
| Indicator | MAIN | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 68.31 | 85.32 |
| Support Level | $57.57 | $213.83 |
| Resistance Level | $63.21 | $241.65 |
| Average True Range (ATR) | 1.04 | 7.92 |
| MACD | 0.65 | 2.15 |
| Stochastic Oscillator | 88.34 | 97.04 |
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.